gbola amusa md cfa head hc research
sale trade et
share mil
creat bluematrix
imvt initi buy larg
initi coverag immunov buy rate
potenti subcutaneously-administ fully-human anti-fcrn
mab achiev first- and/or best-in-class statu larg
igg anti-fcrn therapi offer potenti address unmet medic
need rang autoimmun diseas mediat pathogen igg
antibodi immunov design potenti less
best-in-class part due subq deliveri target indic
anti-fcrn mechan alreadi establish clinic proof-
of-concept first-in-class indic fcrn inhibit clear
biolog rational competit absent inde demonstr
extrem competit pd profil max igg reduct
phase sad/mad trial present may american
academi neurolog meet poster immunov test
first anti-fcrn antibodi subq inject phase ii
trial myasthenia gravi mg grave ophthalmopathi go
indic like announc months/year ahead
proprietari anti-fcrn model model bn risk-adjust
sale figur given opportun earli
imvt perform expect phase ii readout
transit immunov pivotal-phase-iii statu mg make
imvt chardan top pick perform track
share offer follow reason perform
anti-fcrn agent unlik anti-tnf agent could target
exceed billion dollar earli evid suggest
anti-fcrn agent lead rapid catabol igg via lysosom
degrad potenti transform treatment autoimmun
diseas mediat pathogen igg antibodi inde immunov
estim aggreg preval us/eu
initi rare autoimmun diseas fcrn mechan may
relev mg go waiha itp pv cidp bp nmo pf gb
pmn appli price treat everi patient impli
aggreg us/eu market opportun billion provid
enough room multipl anti-fcrn player thrive
deliveri subq inject without need iv
induct high level associ igg reduct may enabl
best-in-class statu variou indic
pleas refer import disclosur inform regul analyst certif found page report
deliv fast minimally-invas subq inject need iv induct
immunov competitor struggl make potent subq formul design incept
best-in-class inject thu avoid common pitfal typic path develop mab iv formul
inde subq competitor gener potenti less potent efgartigimod less conveni
efgartigimod rozanolixizumab and/or yet enter clinic
achiev subq dose enabl at-hom administr fixed-dos regimen lower
likelihood dose error possibl weight-bas dose seen certain competitor
safeti toler data thu far favor albumin reduct headach inject
site reaction rel benign identifi issu far anti-fcrn therapi inde phase
sad/mad trial healthi volunt pbo associ
headach report highest-dos cohort test confirm case anti-drug antibodi multipl dose
cohort treatment-rel seriou advers event sae dose limit toxic albumin reduct
dose-depend asymptomat albumin reduct associ diseas natur seen though
safeti data earli limit number trial particip fully-human antibodi fc
engin reduc effector function expect lower potenti immunogen
initi program mg go waiha associ clear regulatori path clear endpoint
see higher likelihood progress ahead thu rate imvt buy chardan top pick
initi data phase iia ascend-go open label safety/toler pd studi activ
top-line data phase iia ascend-mg double-blind placebo-control safety/toler
pd studi myasthenia gravi mg
initi data phase iia studi warm autoimmun hemolyt anemia waiha
initi pivot phase studi phase iia result myasthenia gravi mg
top-line data phase iib ascend-go double-blind placebo-control safety/
toler pd studi activ moderate-to-sever grave ophthalmopathi go
imvt price target base probability-adjust model key franchis use dcf wacc
perpetu growth impli termin ebitda multipl deriv price target
note though imvt share current trade earn sponsor relat trigger
share describ file see hsac revis definit proxi statement date novemb
model million share dilut estim million basic share count basi million
dilut share count use denomin dcf-deriv valuat immunov
risk achiev target price
platform risk far announc clinical- preclinical-stag asset immunov though
see lower-risk profil note failur asset emerg safeti toler
market-limit issu anti-drug antibodi would profound effect market view valuat
clinic risk expos binari risk surround market percept futur dataset
regulatori may abl gain approv could see regulatori delay even posit clinic data
exampl regul becom comfort long-term safeti anti-fcrn therapi
potenti infect prior approv compet compound
commerci commerci immunov would build global sale market
medic affair infrastructur could increas cash burn way investor consid sub-optimal addit
commerci success may reli abil immunov and/or futur partner manufactur biolog
competit potenti may larg project possibl due competit
note potenti compet anti-fcrn product clinic develop varieti compani includ
argenx unrat mg itp pv cidp ucb unrat rozanolixizumab mg pit cidp alexion
page
unrat waiha gmg partnership privat affibodi
non-anti-fcrn therapi eculizumab gmg ravulizumab-cwvz gmg momenta
unrat nipocalimab mg hdfn waiha
intellectu properti per file patent famili direct composit matter natur
project expir date unit state foreign jurisdict patent hold
least termin valuat immunov would advers affect
financ risk compani may need rais addit capit prior achiev profit accomplish
via equiti financ may result unexpect share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
immunov clinical-stag biopharmaceut compani focus enabl normal live patient
autoimmun diseas immunov lead asset formerli novel fulli human anti-fcrn
monoclon antibodi optim incept subcutan deliveri observ
preclin clinic studi reduc igg antibodi level thu develop autoimmun diseas
robust evid suggest reduct pathogen igg antibodi lead clinic benefit
current phase ii clinic studi myasthenia gravi mg grave ophthalmopathi go expect
enter phase ii clinic studi warm autoimmun hemolyt anemia waiha immunov form juli
began trade decemb
page
initi anti-fcrn market opportun rare autoimmun diseas may exceed billion
chardan sale model bn risk-adjust sale
summari model sale npv indic mg go waiha
chardan myasthenia gravi mg model mm risk-adj sale npv/sh
competit analysi anti-fcrn therapi myasthenia gravi mg edg
chardan grave ophthalmopathi go model mm risk-adj sale npv/sh
chardan waiha model mm risk-adj sale npv/sh
competit analysi anti-fcrn therapi warm autoimmun hemolyt anemia waiha edg
catalyst earli immunov may gener key dataset becom pivot compani
pipelin immunov pipelin product
anti-fcrn therapi may address host autoimmun diseas mediat patholog igg product
phase sad/mad studi test subq fix weight-bas iv fix weight-bas regimen
subq associ potenti best-in-class igg reduct without need iv induct
alreadi lead profil race produc viabl subcutan subq anti-fcrn therapeut
myasthenia gravi could move pivot phase studi year-end
grave ophthalmopathi could becom first fda-approv therapi
warm autoimmun hemolyt anemia could becom one first fda-approv therapi
sale indic
page
initi anti-fcrn market opportun rare autoimmun diseas may exceed billion
adapt immunov januari corpor present chardan
figur anti-fcrn market opportun rare autoimmun total us eu patient exce billion
page
chardan sale model bn risk-adjust sale
summari model sale npv indic mg go waiha
figur posit data expect new indic come on-line support sale growth beyond
page
sale global sale npv/sh across indicationsmyasthenia gravisgrav ophthalmopathywarm antibodi autoimmun hemolyt anemiaunannounc npv/sh immunov inc
chardan myasthenia gravi mg model mm risk-adj sale npv/sh
figur mgwe model launch us price anti-fcrn therapi penetr market share
page
million sale geographyunit state latam sale imvt million sale imvt million yoy statespopul gravi mg treat anti-fcrn treat anti-fcrn anti-fcrn market product efgartigimod rozanolixizumab nipocalimab share year treatment sale imvt yoy immunov inc
competit analysi anti-fcrn therapi myasthenia gravi mg edg
figur mgthough clinically-advanc competit exist competitor lack conveni potent subq option far pivot phase trial
page
namephasetim datatri random double-blind placebo-control patient mgfa class ii-iva qmg score oldsubcutan inject regimen qw ole qw ole placebo wk option ole analysi week baselin level igg subclass week baselin level anti-chr-igg week format subcutan design incept start pivot phase studi phase iia random double-blind patient mg gener muscl weak mgfa class ii iva oldintraven infus regimen efgartigimod regimen placebo mg-adl respond achr -antibodi ab seroposit popul week format fc fragment iv formul achiev igg reduct subq develop success igg reduct less may double-blind patient diagnos gmg ab vs achr musk mgfa class ii-iva mg-adl qmg score oldsubcutan infus rozanolixizumab regimen rozanolixizumab regimen placebo baselin mg-adl score day format compound may show less igg reduct format compound dose-limit random double-blind patient gener mg clinic sign symptom oldintraven infus group placebogroup nipocalimabgroup nipocalimabgroup nipocalimabgroup nipocalimab number particip day baselin total mg-adl score day format intraven approach distinct disadvantag subcutan formul start subq hhv studi complet nananasubcutan injectionna format subcutan formul depend posit result phase studi healthi human volunt start immunov inc
chardan grave ophthalmopathi go model mm risk-adj sale npv/sh
figur gow model launch us price anti-fcrn therapi penetr market share
page
million sale geographyunit state latam sale imvt million sale imvt million yoy statespopul ophthalmopathi go present moderate-to-sever present mild go treat anti-fcrn treat anti-fcrn anti-fcrn market product share share year anti-fcrn treatment sale anti-fcrn therapi yoy immunov inc
chardan waiha model mm risk-adj sale npv/sh
figur waihaw model launch us price anti-fcrn therapi penetr market share
page
million sale geographyunit state latam sale imvt million sale imvt million yoy statespopul hemolyt anemia aiha treat anti-fcrn treat anti-fcrn anti-fcrn market product nipocalimab share year treatment sale imvt yoy immunov inc
competit analysi anti-fcrn therapi warm autoimmun hemolyt anemia waiha edg
figur waihathough competit exist competitor lack conveni potent subq option
page
namephasetim datatri injectionna format subcutan design random double-blind patient diagnos oldintraven infus group nipocalimab nipocalimab placebo particip attain hgb respons week format intraven approach distinct disadvantag subcutan formul start infusionna format compound show less igg reduct format compound dose-limit toxic prior phase i/ii trial use iv infus waiha termin possibl due insuffici igg reduct immunov inc
catalyst earli immunov may gener key dataset becom pivot compani
figur catalyst immunov due report phase ii trial result differ indic mg go waiha becom pivot phase compani
page
dateeventchardan pcd ascend-mg dbpc s/t pd studi pt placebo qw subq pd total igg pcd ascend-go ol s/t pd studi activ m-t- pt qw qw subq pd tot igg igg sub anti-tshr competit pcd pi hhv trial subq pt group singl subq dose endpt igg level across subq competit pcd vivacity-mg dbpct nipocalimab pt group iv endpt baselin mg-adl score day competit pcd phase pc pk/pd trial rozanolixizumab pt group subq endpt relat safeti pk initi data ascend-go ol s/t pd studi activ m-t- pt qw qw subq pd tot igg igg sub anti-tshr competit initi trial prior termin waiha pemphigu competit pcd adapt dbpc trial efgartigimod argx pt iv endpt mg-adl respond achr-ab sero pop top-line data ascend-mg dbpc s/t pd studi pt placebo qw subq pd total igg competit tl vivacity-mg dbpc data nipocalimab pt group iv endpt baselin mg-adl score day initi data phase iia ascend-waiha studi waihath list yet competit initi trial subq gmgthe trial initi subq hhv studi competit tl data dbpc trial efgartigimod argx pt iv endpt mg-adl respond achr-ab sero pop initi pivot studi phase iia ascend-mg result mgmyasthenia gravi could first xachr acetylcholin receptor com composit matter dbpc double-blind placebo-control go grave ophthalmopathi m-t- moderate-to-sever mg myasthenia gravi ol open label pbo placebo pcd primari complet date s/t safeti toler tl top-line waiha warm autoimmun hemolyt anemia immunov inc
figur catalyst beyondin earli phase ii data expect moderate-to-sever go immunov continu pivot phase compani mg
page
dateeventchardan pcd ascend-mg dbpc s/t pd studi pt placebo qw subq pd total igg pcd ascend-go ol s/t pd studi activ m-t- pt qw qw subq pd tot igg igg sub anti-tshr competit pcd pi hhv trial subq pt group singl subq dose endpt igg level across subq competit pcd vivacity-mg dbpct nipocalimab pt group iv endpt baselin mg-adl score day competit pcd phase pc pk/pd trial rozanolixizumab pt group subq endpt relat safeti pk initi data ascend-go ol s/t pd studi activ m-t- pt qw qw subq pd tot igg igg sub anti-tshr competit initi trial prior termin waiha pemphigu competit pcd adapt dbpc trial efgartigimod argx pt iv endpt mg-adl respond achr-ab sero pop top-line data ascend-mg dbpc s/t pd studi pt placebo qw subq pd total igg competit tl vivacity-mg dbpc data nipocalimab pt group iv endpt baselin mg-adl score day initi data phase iia ascend-waiha studi waihath list yet competit initi trial subq gmgthe trial initi subq hhv studi competit tl data dbpc trial efgartigimod argx pt iv endpt mg-adl respond achr-ab sero pop initi pivot studi phase iia ascend-mg result mgmyasthenia gravi could first xachr acetylcholin receptor com composit matter dbpc double-blind placebo-control go grave ophthalmopathi m-t- moderate-to-sever mg myasthenia gravi ol open label pbo placebo pcd primari complet date s/t safeti toler tl top-line waiha warm autoimmun hemolyt anemia immunov inc
pipelin immunov pipelin product
figur program on-going mg go waiha success expect pipelin expans condit like cidp gb itp mn pv
page
product candidatenear-term milestonesww anti-fcrn neonat fc receptor fulli human mab subq warm autoimmun hemolyt anemia waiha initi phase iia dataimmunov north america latam europ nafrica mileston royalti msd-to-mid-teen hanal anti-fcrn neonat fc receptor fulli human mab subq myasthenia gravi mg top-line data phase iia ascend-mg double-blind placebo-control studi initi pivot phase studi phase iia resultsimmunov north america latam europ nafrica mileston royalti msd-to-mid-teen hanal anti-fcrn neonat fc receptor fulli human mab subq grave ophthalmopathi go initi result phase iia ascend-go studi activ moderate-to-sever go top-line data phase iib ascend-go studi activ moderate-to-sever goimmunov north america latam europ nafrica mileston royalti msd-to-mid-teen hanal biopharmastag developmentpreclinphas immunov inc
anti-fcrn therapi may address host autoimmun diseas mediat patholog igg product
adapt immunov decemb corpor present chardan
figur initi proof concept mg go waiha could follow expans target indic
page
phase sad/mad studi test subq fix weight-bas iv fix weight-bas regimen
adapt immunov decemb corpor present chardan
figur phase sad/mad studi design establish fixed-dos subcutan regimen could show util compar iv weight-bas regimen
page
subq associ potenti best-in-class igg reduct without need iv induct
adapt immunov decemb corpor present chardan
figur phase sad/mad produc dose-depend igg reduct left repeat dose right led igg reduct
page
adapt immunov decemb corpor present chardan
figur phase sad/mad produc dose-depend igg reduct across igg subtyp repeat dose led igg reduct across subtyp
page
alreadi lead profil race produc viabl subcutan subq anti-fcrn therapeut
adapt immunov decemb corpor present chardan
figur subq competitor potenti less potent efgartigimod less conveni efgartigimod rozanolixizumab and/or yet enter clinic
page
myasthenia gravi could move pivot phase studi year-end
adapt immunov decemb corpor present chardan
figur edg clinic competitor mgefgartigimod nipocalimab iv infus rozanolixizumab subq infus min subq clinic trial yet
page
grave ophthalmopathi could becom first fda-approv therapi
adapt immunov decemb corpor present chardan
figur clinic competitor far go thu could first-in-class asset condit fda-approv therapi
page
warm autoimmun hemolyt anemia could becom one first fda-approv therapi
adapt immunov decemb corpor present chardan
figur edg clinic competitor waihanipocalimab iv infus iv infus
page
figur immunovantincom statement million except ep
sale indic
figur immunovantproduct revenu million
page
million except gener oper incom incom incom incom incom incom basic dilut ep ep size incom gener oper incom incom incom incom incom incom therapeut piia anti-fcrn mab subq piib anti-fcrn mab subq piia anti-fcrn mab subq pipelin product sale yoy immunov inc
adapt immunov decemb corpor present chardan
figur immunovantdu potenti earn out share count imvt valuat vari ccm use mm share dcf valuat per next page
page
figur immunovantdiscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product net cash fiscal year end fiscal year end project discount project discount per basic share market cap cash per dilut share market cap valu per perpetu growth price hsac novemb chardan share exercis earnout share earnout share hsac sponsor share hsac sponsor share hsac warrant hsac share unvest restrict stock model dilut million immunov inc
